Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I crossover study of DRL-21995, DRL-21994, and Niaspan in healthy adult men
NL-OMON33316Phase 1Active, not recruiting
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DRL-21995, niacin and meloxicam in hyperlipidemia, hypercholesterolemia and lipid disorder (3 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Safety and tolerability, Vasodilatory effect and 1 more. Started Jun 2009; status: active, not recruiting.
02
Drugs
DRL-21995niacinmeloxicam
03
Conditions
hyperlipidemiahypercholesterolemialipid disorder
Beyond the preview
Go deeper on NL-OMON33316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33316.